{
  "docId": "019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "docSlug": "05d98084f9bd31c78a17b84718191aae",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 39,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a three-column layout to present data from three distinct clinical trials, emphasizing hazard ratios (HR) and safety outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-a5cb-72a4-ac7d-0f26e10cd805/32",
  "deckHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "deckJsonHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805.json",
  "deckAnchorHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.36,
        "y": 0.78
      },
      "kind": "callout",
      "text": "...to a HR of 0.20 for mono and 0.1 for combinations in the FL setting",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34f45708-6e08-493e-93d0-d17adfcd9512",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.68,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Non-inferiority on PFS and superiority on AFib",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95c3c61f-7399-4b28-a542-13ed7dd43093",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "callout",
      "text": "From a PFS HR of 0.31 in the R/R setting...",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1df249d-536c-4b12-9612-2786fb74efff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.32
      },
      "kind": "chart",
      "text": "ELEVATE-TN Phase III trial Kaplan-Meier curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14835ccd-2bf2-44ea-9ce7-4bc81d30bd2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "chart",
      "text": "ASCEND Phase III trial Kaplan-Meier curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2f54df1-0f85-4ca3-bf57-8bf0dddf66d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "list",
      "text": "First Phase III trial to evaluate two BTK inhibitors head to head in R/R CLL; Met primary endpoint of non-inferior PFS; Superior safety on key measure of lower atrial fibrillation (AFib)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "233849fc-3ad7-426c-ba4f-10ba86914356",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "IdR = idelalisib BR = bendamustine and rituximab. Source: abstract LB2606, The European Hematology Association 2019. Source: abstract 31, The American Society of Hematology, 2019.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "393ac04d-22c5-4dd0-90b1-67b721e858a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "All data in CLL support a best-in-class potential",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22c9692b-99eb-41e5-a7b0-77ad7818edda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Building new standard of care: Calquence",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1c1c68d-1c6e-4e56-98db-7f5f77be88a0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "cd9b9bc3-b091-4ad6-bdf2-2845c3c44e59",
      "evidence": "The slide uses a clear, thesis-driven headline that summarizes the takeaway of the data presented.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 39,
      "from": 19,
      "beatId": "0e550b23-20ef-4625-a839-81a772e4622a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 34,
      "from": 30,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1f01b495-9cdc-4a8a-89ca-3ee50a905914",
      "evidence": "The document presents pipeline events and growth opportunities",
      "position": 1,
      "objective": "Highlighting pipeline events and growth opportunities",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}